AHA presentation demonstrating the complementary value of the Bodyport Congestion Index and PA pressure monitoring in heart failure patients

Bodyport is a biomarker-guided digital therapeutics company on a mission to address complex chronic conditions by collecting clinically actionable biomarkers from simple, daily experiences. Bodyport captures hemodynamic signals through the Cardiac Scale to power optimized interventions tailored to the patient. By not requiring a wearable device or surgical implant, the solution seamlessly integrates into a patient’s daily life. Bodyport is focused on keeping patients with cardiorenal conditions healthier and out of the hospital. Based in San Francisco, the company is backed by top-tier investors such as Boehringer Ingelheim Venture Fund, Initialized Capital, Playground Global, Rock Health, and Y Combinator. For more information, visit bodyport.com and follow the company on LinkedIn and Twitter.